O
NMRA icon

OrbiMed’s Neumora Therapeutics NMRA Stock Holding History

OrbiMed’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-804,996
Closed -$8.53M – 122
2024
Q4 		$8.53M Sell
804,996
-695,004
-46% -$8.33M 0.18% 73
2024
Q3 		$19.8M Hold
1,500,000
– – 0.36% 64
2024
Q2 		$14.7M Hold
1,500,000
– – 0.29% 64
2024
Q1 		$20.6M Hold
1,500,000
– – 0.38% 63
2023
Q4 		$25.6M Hold
1,500,000
– – 0.51% 56
2023
Q3 		$21.2M Buy
+1,500,000
New +$18.7M 0.45% 61

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

OrbiMed's NMRA Position: Q1 2025 in Review

OrbiMed sold out of Neumora Therapeutics (NMRA) in Q1 2025, closing a stake of 804,996 shares — an estimated $8.53M sold.

OrbiMed first reported a position in NMRA in Q3 2023 and held it in 6 quarters. The position peaked at $25.6M in Q4 2023. 115 funds tracked by Wall St. Rank hold NMRA as of Q1 2025.

  • OrbiMed reported no remaining Neumora Therapeutics position as of Q1 2025 after selling out during the quarter.
  • OrbiMed sold 804,996 Neumora Therapeutics shares in Q1 2025, an estimated $8.53M.
  • OrbiMed first reported a position in Neumora Therapeutics in Q3 2023 and held it in 6 quarters.
  • OrbiMed's Neumora Therapeutics position peaked at $25.6M in Q4 2023.
  • 115 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2025.

Based on OrbiMed's 13F filing for Q1 2025, filed 15 May 2025.